Patent ID: 8389739

Claim:
A method of inhibiting T H -17 cell differentiation from naïve T cells, or inhibiting T H -17 cell function or activity, in an individual having a disorder selected from the group consisting of multiple sclerosis, psoriasis, Crohn's disease, asthma and rheumatoid arthritis, comprising administering an effective amount of a selective small organic molecule antagonist of RORγ to said individual, wherein said small organic molecule antagonist binds to RORγ, has a greater potency at RORγ than at hRARα, and has a molecular weight of less than about 600 daltons, wherein said organic small molecule antagonist of RORγ is selected from the group consisting of OR-885, OR-345, OR-13571, OR-2161, OR-133008, OR-133097, OR-133099, OR-133167, OR-133171, OR-1048, OR-1050 and OR-1047.